Phaseline

Targets › GART

GART (Trifunctional purine biosynthetic protein adenosine-3 [Includes: Phosphoribosylamine--glycine ligase): drug programs, companies and trials

3 programs from 3 companies in 4 trials: 2 Phase 2, 2 Phase 1; Oncology; next expected readout Mar 2027.

Trifunctional enzyme that catalyzes three distinct reactions as part of the 'de novo' inosine monophosphate biosynthetic pathway. (UniProt, P22102)

Open in Phaseline: the race on GART, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Mayo ClinicPemetrexed Disodium
Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; GAR transformylase inhibitor
TYMS, DHFR, GARTPhase 2Metastatic Salivary Gland CarcinomaFeb 2028
NRG OncologyPemetrexed Disodium
Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; GAR transformylase inhibitor
TYMS, DHFR, GARTPhase 2Recurrent Non-Small Cell Lung CarcinomaDec 2028
National Cancer Institute (NCI)Pemetrexed Disodium
Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; GAR transformylase inhibitor
TYMS, DHFR, GARTPhase 1Epithelioid Mesothelioma; Biphasic MesotheliomaMar 2027

Conditions

Recurrent Non-Small Cell Lung Carcinoma (1) Epithelioid Mesothelioma (1) Biphasic Mesothelioma (1) Metastatic Salivary Gland Carcinoma (1)

Modalities

mixed (2), small molecule (1)

Companies

NRG Oncology (1) National Cancer Institute (NCI) (1) Mayo Clinic (1)

Related targets

TYMS (3) DHFR (3)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.